← All Dare Bioscience, INC filings

Dare Bioscience, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
DARE
Dare Bioscience, INC
10-K: Dar Bioscience Faces Going Concern Doubt Amidst Pipeline Advances
Dar Bioscience reported a significant net loss increase in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing its product pipeline and expanding commercial strategies.
NASDAQ
DARE
Dare Bioscience, INC
10-K: Dar Bioscience, Inc. Reports 2024 Annual Results and Outlines Strategic Priorities
Dar Bioscience, Inc. files its 10-K report, highlighting progress in women's health innovation and strategic financial maneuvers.
NASDAQ
DARE
Dare Bioscience, INC
10-K: Dar Bioscience Secures $5 Million Royalty Financing, Issues Warrants
Dar Bioscience enters into a royalty interest financing agreement, selling a portion of future XACIATO royalties for an initial $5 million investment and potential additional funding.